V1 sact_regimen
730,471 rows · 12 columns
| MERGED_REGIMEN_ID | MERGED_TUMOUR_ID | HEIGHT_AT_START_OF_REGIMEN | WEIGHT_AT_START_OF_REGIMEN | INTENT_OF_TREATMENT | DATE_DECISION_TO_TREAT | START_DATE_OF_REGIMEN | MAPPED_REGIMEN | CLINICAL_TRIAL | CHEMO_RADIATION | MERGED_PATIENT_ID | BENCHMARK_GROUP |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 320005735 | 320004095 | 1.69 | 71.35 | Neo-adjuvant (N) | 2014-09-04 | 2014-10-06 | Mitomycin Intravesical | N | N | 320002399 | ATEZOLIZUMAB |
| 320005736 | 320004095 | 1.8 | null | Adjuvant (A) | 2016-04-08 | 2016-04-08 | IBRUTINIB | N | N | 320002399 | IVADO |
| 320005737 | 320004095 | 0 | 49.8 | Palliative (P) | null | 2018-06-02 | ICON8 TRIAL | null | Y | 320002399 | ICON8B TRIAL |
| 320005738 | 320004096 | 1.54 | 65 | null | null | 2018-02-24 | DOXORUBICIN | null | null | 320002615 | BEVACIZUMAB + CARBO + GEMCITABINE |
| 320005739 | 320004097 | 1.7 | 67.9 | Palliative (P) | 2017-03-25 | 2017-03-28 | Cisplatin + Vinorelbine (IV) | N | N | 320003094 | CARBOPLATIN + RT |
| 320005740 | 320004098 | null | null | null | 2018-12-04 | 2018-12-11 | IMATINIB | N | null | 320003483 | NIVOLUMAB |
| 320005741 | 320004099 | null | 55.6 | Palliative (P) | 2016-11-27 | 2016-11-27 | Olaparib | 02 | N | 320003697 | BORTEZOMIB |
| 320005742 | 320005877 | 1.78 | null | Palliative (P) | 2017-12-13 | 2018-01-03 | CAPECITABINE + CARBOPLATIN + Cetuximab | N | null | 320003697 | TCF |
| 320005743 | 320004100 | null | null | Palliative (P) | 2018-09-01 | 2018-09-29 | CARBOPLATIN + CETUXIMAB + FU | N | N | 320003787 | CAPECITABINE + CARBOPLATIN |
| 320005744 | 320004100 | 1.6 | 60.8 | Palliative (P) | 2018-07-14 | 2018-07-24 | CARBOPLATIN + CETUXIMAB + FU | N | N | 320003787 | CARBO + FLUOROURACIL |
| 320005745 | 320004102 | null | null | Neo-adjuvant (N) | 2015-03-10 | 2015-03-20 | VAC | Y | N | 320004049 | CISPLATIN + DOCETAXEL + FLUOROURACIL |
| 320005746 | 320004102 | 1.77 | 64 | null | 2015-08-18 | 2015-08-23 | GEMCITABINE | 2 | N | 320004049 | CAP |
| 320005747 | 320004104 | 1.77 | 97 | Curative (C) | 2018-04-01 | 2018-09-07 | Carboplatin + Cetuximab (>Cycle 2) | N | N | 320004420 | BCG |
| 320005748 | 320004105 | 1.76 | 69 | Neo-adjuvant (N) | 2016-11-02 | 2016-11-16 | Doxorubicin + Gemcitabine | 02 | N | 320004590 | CARBOPLATIN + ETOPOSIDE |
| 320005749 | 320004105 | null | 81.6 | Curative (C) | 2016-08-07 | 2016-08-29 | Bevacizumab + CARBOPLATIN + PACLITAXEL | N | N | 320004590 | CARBOPLATIN + RT |
| 320005750 | 320004107 | 1.71 | 76.3 | Curative (C) | 2018-07-15 | 2018-08-13 | NIVOLUMAB | N | N | 320004814 | ECX |
| 320005751 | 320004107 | 1.72 | 86.2 | Palliative (P) | 2016-04-10 | 2016-04-10 | Docetaxel | N | N | 320004814 | CETUXIMAB + CISPLATIN + FU |
| 320005752 | 320004110 | 1.7 | 77.1 | Palliative (P) | 2017-05-25 | 2017-09-15 | PEMBROLIZUMAB | 2 | N | 320004870 | ICON8B TRIAL |
| 320005753 | 320004111 | 1.73 | null | Neo-adjuvant (N) | null | 2014-01-24 | EMA | null | null | 320004917 | TEMOZOLOMIDE |
| 320005754 | 320004112 | 1.78 | 99.2 | Curative (C) | 2017-05-09 | 2017-05-15 | Docetaxel | N | N | 320005032 | CISPLATIN + FLUOROURACIL + RT |
| 320005755 | 320004112 | null | 73.3 | Palliative (P) | 2016-05-04 | 2016-06-24 | Atezolizumab | 02 | N | 320005032 | GEMCITABINE |
| 320005756 | 320004113 | 1.82 | 15 | Palliative (P) | null | 2018-05-03 | TEMOZOLOMIDE | null | N | 320005289 | BCG |
| 320005757 | 320004113 | 1.64 | null | Palliative (P) | 2018-05-08 | 2018-05-15 | CETUXIMAB + CISPLATIN + FU | 02 | N | 320005289 | IVA |
| 320005758 | 320006724 | 1.6 | 84.4 | Disease modification (D) | 2017-06-09 | 2017-06-17 | Ipilimumab | 02 | N | 320005537 | CARBOPLATIN + CETUXIMAB + FU |
| 320005759 | 320004114 | 1.77 | 74.6 | Adjuvant (A) | null | 2016-02-22 | Cisplatin + Docetaxel +Fluorouracil | null | null | 320005860 | CAP |
| 320005760 | 320005886 | 1.77 | 79.3 | null | 2018-09-06 | 2018-09-12 | CNS Low Grade Glioma Vinblastine | 2 | N | 320006450 | ENZALUTAMIDE |
| 320005761 | 320004115 | 1.76 | 67 | Palliative (P) | 2017-04-30 | 2017-05-13 | STS Rhabdomyosarcoma RMS 2005 IVA | 02 | N | 320006593 | POUT TRIAL |
| 320005762 | 320005887 | 1.5 | 72.9 | Curative (C) | 2016-03-04 | 2016-04-20 | Docetaxel 75mg/m2 (21 day) | N | N | 320006873 | IRINOTECAN + VINCRISTINE |
| 320005763 | 320004116 | null | 109.6 | Neo-adjuvant (N) | null | 2016-12-07 | IMATINIB | null | Y | 320007012 | ATEZOLIZUMAB |
| 320005764 | 320005888 | 1.65 | null | Palliative (P) | 2017-11-30 | 2017-12-11 | Cetuximab+Cisplatin+FU (> Cycle 2) | Y | N | 320007548 | CARBO + FLUOROURACIL |
| 320005765 | 320004117 | 1.57 | 72.45 | Palliative (P) | 2018-01-05 | 2018-01-19 | CETUXIMAB + RT | N | N | 320007680 | BEVACIZUMAB + CARBO + PACLITAXEL |
| 320005766 | 320004118 | 1.61 | 62.4 | Palliative (P) | 2017-08-23 | 2017-09-07 | CMV | N | N | 320007716 | OLAPARIB |
| 320005767 | 320006725 | 1.71 | 64.2 | Not known (9) | 2018-06-21 | 2018-06-23 | CETUXIMAB + RT | 2 | N | 320007731 | CISPLATIN + GEMCITABINE |
| 320005768 | 320006725 | 1.77 | 60 | Adjuvant (A) | 2015-08-20 | 2015-09-17 | Rituximab | N | N | 320007731 | TRABECTEDIN |
| 320005769 | 320004120 | 1.56 | null | Palliative (P) | 2015-10-31 | 2015-11-05 | STS Rhabdo VIT0910 Vinc Irinotecan | N | Y | 320007789 | GEMCITABINE |
| 320005770 | 320004121 | 1.59 | 65.4 | Palliative (P) | 2014-07-03 | 2014-07-03 | Trabectedin | N | N | 320007895 | ICON8B TRIAL |
| 320005771 | 320004121 | null | 67.9 | Curative (C) | 2018-02-26 | 2018-03-03 | Carboplatin+Fluorouracil 4 or 5 day | N | N | 320007895 | PEMBROLIZUMAB |
| 320005772 | 320005891 | 1.6 | 87 | Palliative (P) | 2015-01-21 | 2015-01-21 | Carboplatin + Cetux + FU (>Cycle 2) | 2 | N | 320007902 | RUXOLITINIB |
| 320005773 | 320004125 | 1.75 | null | Palliative (P) | null | 2016-10-25 | CETUXIMAB + RT | null | null | 320007909 | ICON TRIAL |
| 320005774 | 320004125 | 1.56 | 92.4 | Disease modification (D) | 2016-10-02 | 2016-10-18 | POUT TRIAL | Y | Y | 320007909 | IRINOTECAN + BEVACIZUMAB |
| 320005775 | 320004125 | 1.65 | 40 | Curative (C) | 2016-10-14 | 2016-10-19 | CNS LGG 2004 03 vinc weekly+ carbo | Y | N | 320007909 | ICON8B TRIAL |
| 320005776 | 320004128 | 0 | 130 | Palliative (P) | 2016-04-01 | 2016-04-01 | Carboplatin + Etoposide IV 3 day | 02 | N | 320008313 | CISPLATIN + DOCETAXEL + FLUOROURACIL |
| 320005777 | 320004129 | 1.48 | 74 | Neo-adjuvant (N) | 2014-11-23 | 2014-11-27 | Cisplatin + Liposomal Doxorubicin | N | Y | 320008315 | PEMBROLIZUMAB |
| 320005778 | 320004129 | 1.84 | 67.6 | Palliative (P) | 2016-08-16 | 2016-08-20 | AFLIBERCEPT + FU + IRINOTECAN | 02 | N | 320008315 | CVD |
| 320005779 | 320004130 | null | null | Palliative (P) | null | 2016-08-22 | Cetuximab+Cisplatin+FU (> Cycle 2) | null | null | 320008509 | CISPLATIN + GEMCITABINE |
| 320005780 | 320004131 | 1.74 | 50.25 | Palliative (P) | null | 2014-08-28 | Carboplatin + Cetux + FU (>Cycle 2) | null | null | 320008516 | CETUXIMAB + RT |
| 320005781 | 320004132 | 1.78 | 84.8 | Disease modification (D) | 2017-12-11 | 2017-12-15 | Trifluridine + Tipiracil | 02 | N | 320008581 | CARBOPLATIN + RT |
| 320005782 | 320004134 | 1.86 | 53 | Curative (C) | null | 2016-05-05 | CISPLATIN + DOCETAXEL + FLUOROURACIL | N | Y | 320008585 | MITOMYCIN INTRAVESICULAR |
| 320005783 | 320005895 | 1.6 | 72 | Palliative (P) | 2016-04-12 | 2016-04-16 | Temozolomide 200mg/m2 | 02 | N | 320008596 | FLUOROURACIL + MITOMYCIN + RT |
| 320005784 | 320004135 | 1.46 | 17 | Palliative (P) | 2017-07-28 | 2017-07-29 | Temozolomide 200mg/m2 | N | N | 320008611 | CHOP R |